ATE114113T1 - Verwendung von droloxifen bei der behandlung von knochenerkrankungen. - Google Patents

Verwendung von droloxifen bei der behandlung von knochenerkrankungen.

Info

Publication number
ATE114113T1
ATE114113T1 AT92105595T AT92105595T ATE114113T1 AT E114113 T1 ATE114113 T1 AT E114113T1 AT 92105595 T AT92105595 T AT 92105595T AT 92105595 T AT92105595 T AT 92105595T AT E114113 T1 ATE114113 T1 AT E114113T1
Authority
AT
Austria
Prior art keywords
droloxifen
treatment
bone diseases
bone
diseases
Prior art date
Application number
AT92105595T
Other languages
English (en)
Inventor
Kazuaki Niikura
Yoshimitsu Nakajima
Yoshitada Notsu
Ryuji Ono
Osamu Nakayama
Original Assignee
Klinge Co Chem Pharm Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinge Co Chem Pharm Fab filed Critical Klinge Co Chem Pharm Fab
Application granted granted Critical
Publication of ATE114113T1 publication Critical patent/ATE114113T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT92105595T 1991-04-09 1992-04-01 Verwendung von droloxifen bei der behandlung von knochenerkrankungen. ATE114113T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3166944A JPH04312526A (ja) 1991-04-09 1991-04-09 骨疾患治療剤

Publications (1)

Publication Number Publication Date
ATE114113T1 true ATE114113T1 (de) 1994-12-15

Family

ID=15840531

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92105595T ATE114113T1 (de) 1991-04-09 1992-04-01 Verwendung von droloxifen bei der behandlung von knochenerkrankungen.

Country Status (13)

Country Link
US (1) US5254594A (de)
EP (1) EP0509317B1 (de)
JP (1) JPH04312526A (de)
KR (1) KR100196810B1 (de)
AT (1) ATE114113T1 (de)
AU (1) AU648154B2 (de)
CA (1) CA2065093C (de)
DE (1) DE69200675T2 (de)
DK (1) DK0509317T3 (de)
EE (1) EE02971B1 (de)
ES (1) ES2064130T3 (de)
IE (1) IE66900B1 (de)
ZA (1) ZA922527B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
EP0776661A1 (de) * 1992-10-27 1997-06-04 Nippon Kayaku Kabushiki Kaisha Kombinationspreparat eines Antistrogens und eines Glukokortikoids zur Behandlung von Autoimmunkrankheiten
US5886049A (en) 1992-10-27 1999-03-23 Nippon Kayaku Kabushiki Kaisha Remedy for autoimmune diseases
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
DE4401554A1 (de) * 1993-02-16 1994-08-18 Freund Andreas Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
EP0710116B1 (de) * 1993-05-13 2008-09-03 Poniard Pharmaceuticals, Inc. Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
CZ285522B6 (cs) * 1993-06-24 1999-08-11 Eli Lilly And Company Farmaceutický prostředek pro snížení koncentrace glukosy v krvi
US5426123A (en) * 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5455275A (en) * 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
UA41909C2 (uk) 1994-07-22 2001-10-15 Елі Ліллі Енд Компані Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
US5489587A (en) * 1995-01-20 1996-02-06 Eli Lilly And Company Benzofurans used to inhibit bone loss
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
US5985932A (en) * 1996-02-28 1999-11-16 Pfizer Inc Inhibition of autoimmune diseases
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
US5733937A (en) * 1996-02-28 1998-03-31 Pfizer Inc. Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US5726207A (en) * 1996-02-28 1998-03-10 Pfizer Inc. Protection of ischemic myocardium against reperfusion damage
IL120269A0 (en) * 1996-02-28 1997-06-10 Pfizer 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
US5719190A (en) * 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US6110942A (en) * 1996-06-17 2000-08-29 Eli Lilly And Company Method for minimizing the uterotrophic effect of droloxifene
CA2207141A1 (en) * 1996-07-15 1998-01-15 David Thompson Berg Benzothiophene compounds, and uses and formulations thereof
US5792798A (en) * 1996-07-29 1998-08-11 Eli Lilly And Company Method for inhibiting plasminogen activator inhibitor 1
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6114395A (en) * 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
EP0897720A1 (de) * 1997-08-13 1999-02-24 Pfizer Products Inc. Verwendung von droloxifen zur vorbeugung von mammakarzinom
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
BR0013272B1 (pt) * 1999-08-13 2013-10-15 Uso de um inibidor de aromatase esteroidal
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
WO2006052922A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
DK3354276T3 (da) 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
US20090131386A1 (en) * 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002097B1 (de) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalken-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
US4206234A (en) * 1977-08-22 1980-06-03 Imperial Chemical Industries Limited Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency

Also Published As

Publication number Publication date
HK1004257A1 (en) 1998-11-20
CA2065093A1 (en) 1992-10-10
EP0509317A2 (de) 1992-10-21
EP0509317B1 (de) 1994-11-17
DE69200675D1 (de) 1994-12-22
DE69200675T2 (de) 1995-03-16
ES2064130T3 (es) 1995-01-16
DK0509317T3 (da) 1995-01-30
CA2065093C (en) 1995-10-03
AU1399492A (en) 1992-10-15
AU648154B2 (en) 1994-04-14
JPH04312526A (ja) 1992-11-04
EE02971B1 (et) 1997-04-15
IE66900B1 (en) 1996-02-07
KR100196810B1 (ko) 1999-06-15
KR920019342A (ko) 1992-11-19
US5254594A (en) 1993-10-19
EP0509317A3 (en) 1993-03-03
IE921116A1 (en) 1992-10-21
ZA922527B (en) 1992-12-30

Similar Documents

Publication Publication Date Title
ATE114113T1 (de) Verwendung von droloxifen bei der behandlung von knochenerkrankungen.
DE69109560D1 (de) Fungizide Zusammensetzung zur Behandlung von Saatgut.
DE69022249D1 (de) Knochenwachsapplikator zur Behandlung von Knochengewebe.
ATE110556T1 (de) Verbesserungen bei der behandlung von zähnen.
DE59109222D1 (de) Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
DE3579891D1 (de) N-((4,6-dimethoxypyrimidin-2-yl)aminocarbonyl)-3-trifluoromethylpyridin-2-sulfonamide oder salze davon, diese enthaltendes herbizides mittel und verfahren zur herstellung dieser verbindung.
ATE241334T1 (de) Mittel zur förderung des haarwachstums
FI931708A0 (fi) Herbicida substituerade aryl-haloalkylpyrazoler
DE3685633D1 (de) Behandlung von knochenstoerungen.
DE3578611D1 (de) Instrumente zur behandlung von verformten naegeln bei menschlichen patienten.
IT1238825B (it) Dispositivo per la correzione chirurgica dell'ametropia.
DE59104736D1 (de) Knochenchirurgischer Halter.
DE3876288D1 (de) Desinfektions- und sterilisierungsmittel.
ATE12159T1 (de) Desinfektions- und steril isierungszusammensetzung.
DK0750616T3 (da) Syreadditionssalte af 2,3,4,5-tetrahydro-1H-3-benzazapinforbindelser
ES2073391T3 (es) Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
ATE129895T1 (de) Behandlung von pulmonarer disfunktion mit 15-keto-prostaglandin-derivaten.
FI892207A7 (fi) 2-adamantyyli-4-isotiatsolin-3-onit, niiden valmistusmenetelmä ja käyttö bakteereita ja sieniä tuohoavina aineina
DE69124415D1 (de) Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE68905076D1 (de) Pharmazeutische zusammensetzung fuer die behandlung von hautwunden.
ATE67931T1 (de) Butylhydroxyanisole zur behandlung von retrovirus-krankheiten.
DE3772047D1 (de) Pyrazin zur behandlung von haemodynamischen und metabolischen krankheiten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee